- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03828123
Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis (AMSC-ALS-001)
A Prospective, Non-randomized, Open Label Study to Assess the Safety and the Efficacy of Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- established diagnosis of definite ALS according to El Escorial criteria
- riluzole naive or stable dose for at least 2 months,
- life expectancy more than 2 years
- patients able to provide written informed consent.
Exclusion Criteria:
- FVC less than 70%
- in case of primary bulbar paralysis less than 15 points on Norris bulbar scale,
- less than 15 points on Norris spinal scale,
- pregnancy, breastfeeding
- coagulopathy,
- skin infection at the site of bone marrow aspiration or application of the cell product,
- gastrostomy,
- any significant medical condition that would compromise the safety of the patient (e.g. recent myocardial infarction, congestive heart failure, renal failure, liver failure, cancer, systemic infection, recurrent thromboembolic disease .....),
- alcohol or drug abuse
- cancer.
- women of childbearing potential not using effective contraception (established oral contraception, intrauterine device, ligation of the uterine tube) including proven contraceptive measures taken by their sexual partners
- fertile men not using proven contraceptive measures including effective contraception of their partner (established oral contraception, intrauterine device, ligation of the uterine tube)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Autologous Multipotent MSC
Patients with intrathecal administration of Suspension of human autologous MSC 3P in 1.5 ml
|
Intrathecal application of Autologous Multipotent Mesenchymal Stromal Cells 3P suspension
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Complications related to the medicinal product application - new neurological deficit and occurrence of other adverse events
Time Frame: 1 year
|
Complications at the site of intrathecal infusion of the medicinal product and no new neurological deficit (meningism, paraplegia, urinary incontinence) not attributed to the natural progression of the ALS disease will be recorded at Visits I, III, IV, V, VI, and IX. Occurrence of other potential adverse events, including headache, respiratory failure, leukocytosis, cervical spine stenosis, cystitis and hyperhydrosis will be evaluated on the severity scale (1=mild, 2=moderate, 3=severe). Brain and spinal cord MRI will be performed at Visits I and IX to exclude treatment-related tumor formation, pathological contrast enhancement or other structural pathology. |
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy: Inhibition of the disease progression - ALS functional rating scale
Time Frame: 18 months
|
Inhibition of the disease progression will be recorded by ALS functional rating scale (ALSFRS) at Visits I, III, and VI through X. Measures (all 4-0):
ALSFRS = SUM (points for all 10 measures) Interpretation: minimum score: 0 maximum score: 40 The higher the score the more function is retained. |
18 months
|
Efficacy: Inhibition of the disease progression - Norris scale
Time Frame: 18 months
|
Inhibition of the disease progression will be recorded by Norris scale at Visits I, III, and VI through X. Norris scal has has 22 items examining bulbar, respiratory, trunk, arm, leg, and general domains involving reflexes, fasciculation, and muscle atrophy. The scale also measures emotional lability, fatigability and leg rigidity. The Norris scale has a linear decline during the course of ALS. |
18 months
|
Efficacy: Inhibition of the disease progression - Forced vital capacity (FVC)
Time Frame: 18 months
|
FVC (%) will be measured at Visits I, and VI through X.
|
18 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMSC-ALS-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Motor Neuron Disease, Amyotrophic Lateral Sclerosis
-
Ambulanzpartner Soziotechnologie APST GmbHCharite University, Berlin, GermanyRecruitingMotor Neuron Disease, Amyotrophic Lateral SclerosisGermany
-
Washington University School of MedicineEnrolling by invitationMotor Neuron Disease | Amyotrophic Lateral Sclerosis | Lou Gehrig Disease | Familial Amyotrophic Lateral Sclerosis | Motor Neuron Disease, FamilialUnited States
-
University of EdinburghUniversity College, London; NHS Lothian; University of WarwickRecruitingMotor Neuron Disease, Amyotrophic Lateral SclerosisUnited Kingdom
-
Azienda Socio Sanitaria Territoriale degli Spedali...CompletedAmyotrophic Lateral Sclerosis With Dementia | Motor Neuron Disease, FamilialItaly
-
University of MelbourneMonash University; Western Sydney Local Health District; Royal Prince Alfred... and other collaboratorsRecruitingMotor Neuron Disease / Amyotrophic Lateral SclerosisAustralia
-
Biohaven Pharmaceuticals, Inc.Cognitive Research CorporationCompletedAmyotrophic Lateral Sclerosis | ALS | Lou Gehrig Disease | Lou Gehrig's Disease | Lou-Gehrigs Disease | Motor Neuron Disease, Amyotrophic Lateral SclerosisUnited States
-
Biohaven Pharmaceuticals, Inc.No longer availableAmyotrophic Lateral Sclerosis | ALS | Lou Gehrig Disease | Lou Gehrig's Disease | Lou-Gehrigs Disease | Motor Neuron Disease, Amyotrophic Lateral Sclerosis
-
Liverpool University Hospitals NHS Foundation TrustNot yet recruitingMotor Neuron Disease, Amyotrophic Lateral Sclerosis
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownALS (Amyotrophic Lateral Sclerosis) | MND (Motor Neurone DIsease)United Kingdom
-
Washington University School of MedicineMassachusetts General HospitalSuspendedAmyotrophic Lateral Sclerosis, Familial | Amyotrophic Lateral Sclerosis, SporadicUnited States
Clinical Trials on Suspension of human autologous MSC 3P in 1.5 ml
-
Bioinova, s.r.o.Department of Spine Surgery, University Hospital Motol, Prague, Czech RepublilcTerminated
-
Bioinova, s.r.o.Department of Neurology, University Hospital Motol, Prague, Czech RepublicTerminated
-
Clovis Oncology, Inc.CompletedAdvanced Solid TumorNetherlands
-
Federal University of São PauloCompletedAge Related Macular Degeneration | Exudative Age-related Macular Degeneration | Stargardt's DiseaseBrazil
-
Frank LippertThe Borrow FoundationCompleted
-
Hadassah Medical OrganizationTerminated
-
Supergenics Life Science Sdn. Bhd.Not yet recruitingDiabetic Foot Ulcer
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 2 | Acute Myocardial InfarctionCanada, Croatia, Czech Republic, Germany, Hungary, India, Israel, Lebanon, Poland, Romania, Russian Federation, Slovakia, Slovenia, South Africa, Spain, Turkey, United Kingdom
-
Institute of Medical Biology, Chinese Academy of...Hubei Provincial Center for Disease Control and PreventionActive, not recruitingEpidemic Parotitis,MumpsChina
-
Andrews Research & Education FoundationPacira Pharmaceuticals, IncSuspendedRotator Cuff TearUnited States